REFERENCES
1. Fustin JM, Doi M, Yamaguchi Y, et al. RNA-methylation-dependent RNA processing controls the speed of the circadian clock. Cell 2013;155:793-806.
2. Wilson DM 3rd, Cookson MR, Van Den Bosch L, Zetterberg H, Holtzman DM, Dewachter I. Hallmarks of neurodegenerative diseases. Cell 2023;186:693-714.
4. Long JM, Holtzman DM. Alzheimer disease: an update on pathobiology and treatment strategies. Cell 2019;179:312-39.
5. Chen WW, Zhang X, Huang WJ. Role of neuroinflammation in neurodegenerative diseases (Review). Mol Med Rep 2016;13:3391-6.
7. Przedborski S. The two-century journey of Parkinson disease research. Nat Rev Neurosci 2017;18:251-9.
9. Taylor JP, Brown RH Jr, Cleveland DW. Decoding ALS: from genes to mechanism. Nature 2016;539:197-206.
10. Lieberman AP, Shakkottai VG, Albin RL. Polyglutamine repeats in neurodegenerative diseases. Annu Rev Pathol 2019;14:1-27.
11. Paulson HL, Shakkottai VG, Clark HB, Orr HT. Polyglutamine spinocerebellar ataxias - from genes to potential treatments. Nat Rev Neurosci 2017;18:613-26.
12. Gatchel JR, Zoghbi HY. Diseases of unstable repeat expansion: mechanisms and common principles. Nat Rev Genet 2005;6:743-55.
13. Sonvane S, Choudhari P, Bhusnuare O. In silico analysis of polyphenols and flavonoids for design of human Nav1.7 inhibitors. J Biomol Struct Dyn 2021;39:4472-9.
14. Twarowski B, Herbet M. Inflammatory processes in Alzheimer’s disease-pathomechanism, diagnosis and treatment: a review. Int J Mol Sci 2023;24:6518.
15. Erkkinen MG, Kim MO, Geschwind MD. Clinical neurology and epidemiology of the major neurodegenerative diseases. Cold Spring Harb Perspect Biol 2018;10:a033118.
16. Stopschinski BE, Del Tredici K, Estill-Terpack SJ, et al. Anatomic survey of seeding in Alzheimer’s disease brains reveals unexpected patterns. Acta Neuropathol Commun 2021;9:164.
17. Arnsten AFT, Datta D, Del Tredici K, Braak H. Hypothesis: tau pathology is an initiating factor in sporadic Alzheimer’s disease. Alzheimers Dement 2021;17:115-24.
18. Patke A, Young MW, Axelrod S. Molecular mechanisms and physiological importance of circadian rhythms. Nat Rev Mol Cell Biol 2020;21:67-84.
19. Jones JR, Chaturvedi S, Granados-Fuentes D, Herzog ED. Circadian neurons in the paraventricular nucleus entrain and sustain daily rhythms in glucocorticoids. Nat Commun 2021;12:5763.
20. Stokkan KA, Yamazaki S, Tei H, Sakaki Y, Menaker M. Entrainment of the circadian clock in the liver by feeding. Science 2001;291:490-3.
21. Labarbera VA, Sharkey KM. Review of protocols and terminology to enhance understanding of circadian-based literature. In: Auger R, editor. Circadian rhythm sleep-wake disorders. Cham: Springer; 2020. pp. 21-7.
22. Brown MR, Matveyenko AV. Biological timekeeping: scientific background. In:Auger R, editor. Circadian rhythm sleep-wake disorders: an evidence-based guide for clinicians and investigators. Cham: Springer; 2020. pp. 1-20.
23. Micic G, Lovato N, Ferguson SA, Burgess HJ, Lack L. Circadian tau differences and rhythm associations in delayed sleep-wake phase disorder and sighted non-24-hour sleep-wake rhythm disorder. Sleep 2021;44:zsaa132.
24. Berson DM, Dunn FA, Takao M. Phototransduction by retinal ganglion cells that set the circadian clock. Science 2002;295:1070-3.
25. Hattar S, Liao HW, Takao M, Berson DM, Yau KW. Melanopsin-containing retinal ganglion cells: architecture, projections, and intrinsic photosensitivity. Science 2002;295:1065-70.
26. Aton SJ, Herzog ED. Come together, right...now: synchronization of rhythms in a mammalian circadian clock. Neuron 2005;48:531-4.
27. Colwell CS, Michel S, Itri J, et al. Disrupted circadian rhythms in VIP- and PHI-deficient mice. Am J Physiol Regul Integr Comp Physiol 2003;285:R939-49.
28. Edwards MD, Brancaccio M, Chesham JE, Maywood ES, Hastings MH. Rhythmic expression of cryptochrome induces the circadian clock of arrhythmic suprachiasmatic nuclei through arginine vasopressin signaling. Proc Natl Acad Sci U S A 2016;113:2732-7.
29. Maywood ES, Chesham JE, O'Brien JA, Hastings MH. A diversity of paracrine signals sustains molecular circadian cycling in suprachiasmatic nucleus circuits. Proc Natl Acad Sci U S A 2011;108:14306-11.
30. Mieda M, Ono D, Hasegawa E, et al. Cellular clocks in AVP neurons of the SCN are critical for interneuronal coupling regulating circadian behavior rhythm. Neuron 2015;85:1103-16.
31. Varadarajan S, Tajiri M, Jain R, et al. Connectome of the suprachiasmatic nucleus: new evidence of the core-shell relationship. eNeuro 2018;5:ENEURO.0205-18.2018.
32. Balsalobre A, Brown SA, Marcacci L, et al. Resetting of circadian time in peripheral tissues by glucocorticoid signaling. Science 2000;289:2344-7.
33. Reddy AB, Maywood ES, Karp NA, et al. Glucocorticoid signaling synchronizes the liver circadian transcriptome. Hepatology 2007;45:1478-88.
34. So AY, Bernal TU, Pillsbury ML, Yamamoto KR, Feldman BJ. Glucocorticoid regulation of the circadian clock modulates glucose homeostasis. Proc Natl Acad Sci U S A 2009;106:17582-7.
35. Franzago M, Alessandrelli E, Notarangelo S, Stuppia L, Vitacolonna E. Chrono-nutrition: circadian rhythm and personalized nutrition. Int J Mol Sci 2023;24:2571.
36. Allada R, White NE, So WV, Hall JC, Rosbash M. A mutant Drosophila homolog of mammalian Clock disrupts circadian rhythms and transcription of period and timeless. Cell 1998;93:791-804.
37. Sehgal A, Price JL, Man B, Young MW. Loss of circadian behavioral rhythms and per RNA oscillations in the Drosophila mutant timeless. Science 1994;263:1603-6.
38. Rutila JE, Suri V, Le M, So WV, Rosbash M, Hall JC. CYCLE is a second bHLH-PAS clock protein essential for circadian rhythmicity and transcription of Drosophila period and timeless. Cell 1998;93:805-14.
39. Glossop NR, Lyons LC, Hardin PE. Interlocked feedback loops within the Drosophila circadian oscillator. Science 1999;286:766-8.
40. Meyer P, Saez L, Young MW. PER-TIM interactions in living Drosophila cells: an interval timer for the circadian clock. Science 2006;311:226-9.
41. Ceriani MF, Darlington TK, Staknis D, et al. Light-dependent sequestration of TIMELESS by CRYPTOCHROME. Science 1999;285:553-6.
42. Kloss B, Price JL, Saez L, et al. The Drosophila clock gene double-time encodes a protein closely related to human casein kinase Iepsilon. Cell 1998;94:97-107.
43. Price JL, Blau J, Rothenfluh A, Abodeely M, Kloss B, Young MW. double-time is a novel Drosophila clock gene that regulates PERIOD protein accumulation. Cell 1998;94:83-95.
44. Plautz JD, Kaneko M, Hall JC, Kay SA. Independent photoreceptive circadian clocks throughout Drosophila. Science 1997;278:1632-5.
45. Whitmore D, Foulkes NS, Sassone-Corsi P. Light acts directly on organs and cells in culture to set the vertebrate circadian clock. Nature 2000;404:87-91.
46. Tosini G, Menaker M. Multioscillatory circadian organization in a vertebrate, iguana iguana. J Neurosci 1998;18:1105-14.
47. Mohawk JA, Green CB, Takahashi JS. Central and peripheral circadian clocks in mammals. Annu Rev Neurosci 2012;35:445-62.
48. Gamble KL, Berry R, Frank SJ, Young ME. Circadian clock control of endocrine factors. Nat Rev Endocrinol 2014;10:466-75.
49. Hood S, Amir S. The aging clock: circadian rhythms and later life. J Clin Invest 2017;127:437-46.
50. Kojima S, Gendreau KL, Sher-Chen EL, Gao P, Green CB. Changes in poly(A) tail length dynamics from the loss of the circadian deadenylase Nocturnin. Sci Rep 2015;5:17059.
51. Laothamatas I, Gao P, Wickramaratne A, et al. Spatiotemporal regulation of NADP(H) phosphatase Nocturnin and its role in oxidative stress response. Proc Natl Acad Sci U S A 2020;117:993-9.
52. Wang Y, Osterbur DL, Megaw PL, et al. Rhythmic expression of Nocturnin mRNA in multiple tissues of the mouse. BMC Dev Biol 2001;1:9.
53. Koike N, Yoo SH, Huang HC, et al. Transcriptional architecture and chromatin landscape of the core circadian clock in mammals. Science 2012;338:349-54.
54. Ripperger JA, Schibler U. Rhythmic CLOCK-BMAL1 binding to multiple E-box motifs drives circadian Dbp transcription and chromatin transitions. Nat Genet 2006;38:369-74.
55. Liu C, Chung M. Genetics and epigenetics of circadian rhythms and their potential roles in neuropsychiatric disorders. Neurosci Bull 2015;31:141-59.
56. Doi M, Hirayama J, Sassone-Corsi P. Circadian regulator CLOCK is a histone acetyltransferase. Cell 2006;125:497-508.
57. Hirayama J, Sahar S, Grimaldi B, et al. CLOCK-mediated acetylation of BMAL1 controls circadian function. Nature 2007;450:1086-90.
58. Asher G, Gatfield D, Stratmann M, et al. SIRT1 regulates circadian clock gene expression through PER2 deacetylation. Cell 2008;134:317-28.
59. Nakahata Y, Kaluzova M, Grimaldi B, et al. The NAD+-dependent deacetylase SIRT1 modulates CLOCK-mediated chromatin remodeling and circadian control. Cell 2008;134:329-40.
60. Etchegaray JP, Lee C, Wade PA, Reppert SM. Rhythmic histone acetylation underlies transcription in the mammalian circadian clock. Nature 2003;421:177-82.
61. Curtis AM, Seo S, Westgate EJ, et al. Histone acetyltransferase-dependent chromatin remodeling and the vascular clock. J Biol Chem 2004;279:7091-7.
62. Johansson AS, Brask J, Owe-Larsson B, Hetta J, Lundkvist GBS. Valproic acid phase shifts the rhythmic expression of Period2::Luciferase. J Biol Rhythms 2011;26:541-51.
63. Alenghat T, Meyers K, Mullican SE, et al. Nuclear receptor corepressor and histone deacetylase 3 govern circadian metabolic physiology. Nature 2008;456:997-1000.
64. Feng D, Liu T, Sun Z, et al. A circadian rhythm orchestrated by histone deacetylase 3 controls hepatic lipid metabolism. Science 2011;331:1315-9.
65. Papazyan R, Zhang Y, Lazar MA. Genetic and epigenomic mechanisms of mammalian circadian transcription. Nat Struct Mol Biol 2016;23:1045-52.
66. Duong HA, Weitz CJ. Temporal orchestration of repressive chromatin modifiers by circadian clock Period complexes. Nat Struct Mol Biol 2014;21:126-32.
67. Etchegaray JP, Yang X, DeBruyne JP, et al. The polycomb group protein EZH2 is required for mammalian circadian clock function. J Biol Chem 2006;281:21209-15.
68. Yue M, Yang Y, Guo GL, Qin XM. Genetic and epigeneticregulations of mammalian circadian rhythms. Yi Chuan 2017;39:1122-37.
69. Nam HJ, Boo K, Kim D, et al. Phosphorylation of LSD1 by PKCα is crucial for circadian rhythmicity and phase resetting. Mol Cell 2014;53:791-805.
70. Jones MA, Covington MF, DiTacchio L, Vollmers C, Panda S, Harmer SL. Jumonji domain protein JMJD5 functions in both the plant and human circadian systems. Proc Natl Acad Sci U S A 2010;107:21623-8.
71. Sasso JM, Ambrose BJB, Tenchov R, et al. The progress and promise of RNA medicine - an arsenal of targeted treatments. J Med Chem 2022;65:6975-7015.
72. Musiek ES, Holtzman DM. Three dimensions of the amyloid hypothesis: time, space and ‘wingmen’. Nat Neurosci 2015;18:800-6.
73. Huang Y, Potter R, Sigurdson W, et al. Effects of age and amyloid deposition on Aβ dynamics in the human central nervous system. Arch Neurol 2012;69:51-8.
74. Nepovimova E, Janockova J, Misik J, et al. Orexin supplementation in narcolepsy treatment: a review. Med Res Rev 2019;39:961-75.
75. Benedict C, Byberg L, Cedernaes J, et al. Self-reported sleep disturbance is associated with Alzheimer’s disease risk in men. Alzheimers Dement 2015;11:1090-7.
76. Osorio RS, Ducca EL, Wohlleber ME, et al. Orexin-A is associated with increases in cerebrospinal fluid phosphorylated-tau in cognitively normal elderly subjects. Sleep 2016;39:1253-60.
77. Videnovic A, Lazar AS, Barker RA, Overeem S. ‘The clocks that time us’ - circadian rhythms in neurodegenerative disorders. Nat Rev Neurol 2014;10:683-93.
78. Canevelli M, Valletta M, Trebbastoni A, et al. Sundowning in dementia: clinical relevance, pathophysiological determinants, and therapeutic approaches. Front Med 2016;3:73.
80. Musiek ES, Bhimasani M, Zangrilli MA, Morris JC, Holtzman DM, Ju YS. Circadian rest-activity pattern changes in aging and preclinical Alzheimer disease. JAMA Neurol 2018;75:582-90.
81. Naismith SL, Hickie IB, Terpening Z, et al. Circadian misalignment and sleep disruption in mild cognitive impairment. J Alzheimers Dis 2014;38:857-66.
82. La Morgia C, Ross-Cisneros FN, Koronyo Y, et al. Melanopsin retinal ganglion cell loss in Alzheimer disease. Ann Neurol 2016;79:90-109.
83. Liguori C, Romigi A, Nuccetelli M, et al. Orexinergic system dysregulation, sleep impairment, and cognitive decline in Alzheimer disease. JAMA Neurol 2014;71:1498-505.
84. Wang JL, Lim AS, Chiang WY, et al. Suprachiasmatic neuron numbers and rest-activity circadian rhythms in older humans. Ann Neurol 2015;78:317-22.
85. Hooghiemstra AM, Eggermont LH, Scheltens P, van der Flier WM, Scherder EJ. The rest-activity rhythm and physical activity in early-onset dementia. Alzheimer Dis Assoc Disord 2015;29:45-9.
86. Weissová K, Bartoš A, Sládek M, Nováková M, Sumová A. Moderate changes in the circadian system of Alzheimer’s disease patients detected in their home environment. PLoS One 2016;11:e0146200.
87. Videnovic A, Noble C, Reid KJ, et al. Circadian melatonin rhythm and excessive daytime sleepiness in Parkinson disease. JAMA Neurol 2014;71:463-9.
88. Tholfsen LK, Larsen JP, Schulz J, Tysnes OB, Gjerstad MD. Development of excessive daytime sleepiness in early Parkinson disease. Neurology 2015;85:162-8.
89. Breen DP, Vuono R, Nawarathna U, et al. Sleep and circadian rhythm regulation in early Parkinson disease. JAMA Neurol 2014;71:589-95.
90. Zhong G, Bolitho S, Grunstein R, Naismith SL, Lewis SJ. The relationship between thermoregulation and REM sleep behaviour disorder in Parkinson’s disease. PLoS One 2013;8:e72661.
91. Berganzo K, Díez-Arrola B, Tijero B, et al. Nocturnal hypertension and dysautonomia in patients with Parkinson’s disease: are they related? J Neurol 2013;260:1752-6.
92. Bolitho SJ, Naismith SL, Rajaratnam SMW, et al. Disturbances in melatonin secretion and circadian sleep-wake regulation in Parkinson disease. Sleep Med 2014;15:342-7.
93. van Wamelen DJ, Podlewska AM, Leta V, et al. Slave to the rhythm: Seasonal differences in non-motor symptoms in Parkinson’s disease. Parkinsonism Relat Disord 2019;63:73-6.
94. Dorcikova M, Duret LC, Pottié E, Nagoshi E. Circadian clock disruption promotes the degeneration of dopaminergic neurons in male Drosophila. Nat Commun 2023;14:5908.
95. Kou L, Chi X, Sun Y, et al. Circadian regulation of microglia function: potential targets for treatment of Parkinson’s disease. Ageing Res Rev 2024;95:102232.
96. Fonken LK, Frank MG, Kitt MM, Barrientos RM, Watkins LR, Maier SF. Microglia inflammatory responses are controlled by an intrinsic circadian clock. Brain Behav Immun 2015;45:171-9.
97. Choudhury ME, Miyanishi K, Takeda H, et al. Phagocytic elimination of synapses by microglia during sleep. Glia 2020;68:44-59.
98. Morawska MM, Moreira CG, Ginde VR, et al. Slow-wave sleep affects synucleinopathy and regulates proteostatic processes in mouse models of Parkinson’s disease. Sci Transl Med 2021;13:eabe7099.
99. Kou L, Chi X, Sun Y, et al. The circadian clock protein Rev-erbα provides neuroprotection and attenuates neuroinflammation against Parkinson’s disease via the microglial NLRP3 inflammasome. J Neuroinflammation 2022;19:133.
100. Chahine LM, Amara AW, Videnovic A. A systematic review of the literature on disorders of sleep and wakefulness in Parkinson’s disease from 2005 to 2015. Sleep Med Rev 2017;35:33-50.
101. Hunt J, Coulson EJ, Rajnarayanan R, Oster H, Videnovic A, Rawashdeh O. Sleep and circadian rhythms in Parkinson’s disease and preclinical models. Mol Neurodegener 2022;17:2.
102. Liu S, Huang Y, Tai H, et al. Excessive daytime sleepiness in Chinese patients with sporadic amyotrophic lateral sclerosis and its association with cognitive and behavioural impairments. J Neurol Neurosurg Psychiatry 2018;89:1038-43.
103. González-Naranjo JE, Alfonso-Alfonso M, Grass-Fernandez D, et al. Analysis of sleep macrostructure in patients diagnosed with Parkinson’s disease. Behav Sci 2019;9:6.
104. Boentert M. Sleep disturbances in patients with amyotrophic lateral sclerosis: current perspectives. Nat Sci Sleep 2019;11:97-111.
105. Ahmed RM, Newcombe RE, Piper AJ, et al. Sleep disorders and respiratory function in amyotrophic lateral sclerosis. Sleep Med Rev 2016;26:33-42.
106. D’Cruz RF, Murphy PB, Kaltsakas G. Sleep disordered breathing in motor neurone disease. J Thorac Dis 2018;10:S86-93.
107. Choquer M, Blasco H, Plantier L, et al. Insomnia is frequent in amyotrophic lateral sclerosis at the time of diagnosis. Sleep Biol Rhythms 2021;19:121-6.
108. Zhang Y, Ren R, Yang L, et al. Sleep in Huntington’s disease: a systematic review and meta-analysis of polysomongraphic findings. Sleep 2019;42:zsz154.
109. Aziz NA, Pijl H, Frölich M, et al. Delayed onset of the diurnal melatonin rise in patients with Huntington’s disease. J Neurol 2009;256:1961-5.
110. Morton AJ, Wood NI, Hastings MH, Hurelbrink C, Barker RA, Maywood ES. Disintegration of the sleep-wake cycle and circadian timing in Huntington’s disease. J Neurosci 2005;25:157-63.
111. Morton AJ, Rudiger SR, Wood NI, et al. Early and progressive circadian abnormalities in Huntington’s disease sheep are unmasked by social environment. Hum Mol Genet 2014;23:3375-83.
112. Mueller SM, Petersen JA, Jung HH. Exercise in Huntington’s disease: current state and clinical significance. Tremor Other Hyperkinet Mov 2019;9:601.
113. Pallier PN, Morton AJ. Management of sleep/wake cycles improves cognitive function in a transgenic mouse model of Huntington’s disease. Brain Res 2009;1279:90-8.
114. Maywood ES, Fraenkel E, McAllister CJ, et al. Disruption of peripheral circadian timekeeping in a mouse model of Huntington’s disease and its restoration by temporally scheduled feeding. J Neurosci 2010;30:10199-204.
115. Voysey Z, Fazal SV, Lazar AS, Barker RA. The sleep and circadian problems of Huntington’s disease: when, why and their importance. J Neurol 2021;268:2275-83.
116. Aditi K, Singh A, Shakarad MN, Agrawal N. Management of altered metabolic activity in Drosophila model of Huntington’s disease by curcumin. Exp Biol Med 2022;247:152-64.
117. Oyegbami O, Collins HM, Pardon MC, Ebling FJP, Heery DM, Moran PM. Abnormal clock gene expression and locomotor activity rhythms in two month-old female APPSwe/PS1dE9 mice. Curr Alzheimer Res 2017;14:850-60.
118. Stevanovic K, Yunus A, Joly-Amado A, et al. Disruption of normal circadian clock function in a mouse model of tauopathy. Exp Neurol 2017;294:58-67.
119. Duncan MJ, Smith JT, Franklin KM, et al. Effects of aging and genotype on circadian rhythms, sleep, and clock gene expression in APPxPS1 knock-in mice, a model for Alzheimer’s disease. Exp Neurol 2012;236:249-58.
120. Kang JE, Lim MM, Bateman RJ, et al. Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science 2009;326:1005-7.
121. Song H, Moon M, Choe HK, et al. Aβ-induced degradation of BMAL1 and CBP leads to circadian rhythm disruption in Alzheimer’s disease. Mol Neurodegener 2015;10:13.
122. Leng Y, Musiek ES, Hu K, Cappuccio FP, Yaffe K. Association between circadian rhythms and neurodegenerative diseases. Lancet Neurol 2019;18:307-18.
123. Lucey BP, Hicks TJ, McLeland JS, et al. Effect of sleep on overnight cerebrospinal fluid amyloid β kinetics. Ann Neurol 2018;83:197-204.
124. Meco A, Joshi YB, Praticò D. Sleep deprivation impairs memory, tau metabolism, and synaptic integrity of a mouse model of Alzheimer’s disease with plaques and tangles. Neurobiol Aging 2014;35:1813-20.
125. Rothman SM, Herdener N, Frankola KA, Mughal MR, Mattson MP. Chronic mild sleep restriction accentuates contextual memory impairments, and accumulations of cortical Aβ and pTau in a mouse model of Alzheimer’s disease. Brain Res 2013;1529:200-8.
126. Hogenkamp PS, Nilsson E, Nilsson VC, et al. Acute sleep deprivation increases portion size and affects food choice in young men. Psychoneuroendocrinology 2013;38:1668-74.
127. Xie L, Kang H, Xu Q, et al. Sleep drives metabolite clearance from the adult brain. Science 2013;342:373-7.
128. de Vivo L, Bellesi M, Marshall W, et al. Ultrastructural evidence for synaptic scaling across the wake/sleep cycle. Science 2017;355:507-10.
129. Curtis AM, Bellet MM, Sassone-Corsi P, O’Neill LA. Circadian clock proteins and immunity. Immunity 2014;40:178-86.
130. Curtis AM, Fagundes CT, Yang G, et al. Circadian control of innate immunity in macrophages by miR-155 targeting Bmal1. Proc Natl Acad Sci U S A 2015;112:7231-6.
131. Druzd D, Matveeva O, Ince L, et al. Lymphocyte circadian clocks control lymph node trafficking and adaptive immune responses. Immunity 2017;46:120-32.
132. Sutton CE, Finlay CM, Raverdeau M, et al. Loss of the molecular clock in myeloid cells exacerbates T cell-mediated CNS autoimmune disease. Nat Commun 2017;8:1923.
133. Kanan MF, Sheehan PW, Haines JN, et al. Neuronal deletion of the circadian clock gene Bmal1 induces cell-autonomous dopaminergic neurodegeneration. JCI Insight 2024;9:e162771.
134. Hayashi Y, Koyanagi S, Kusunose N, et al. The intrinsic microglial molecular clock controls synaptic strength via the circadian expression of cathepsin S. Sci Rep 2013;3:2744.
135. Musiek ES, Lim MM, Yang G, et al. Circadian clock proteins regulate neuronal redox homeostasis and neurodegeneration. J Clin Invest 2013;123:5389-400.
136. Huang Z, Liu Q, Peng Y, et al. Circadian rhythm dysfunction accelerates disease progression in a mouse model with amyotrophic lateral sclerosis. Front Neurol 2018;9:218.
137. Lauretti E, Di Meco A, Merali S, Praticò D. Circadian rhythm dysfunction: a novel environmental risk factor for Parkinson’s disease. Mol Psychiatry 2017;22:280-6.
138. Kress GJ, Liao F, Dimitry J, et al. Regulation of amyloid-β dynamics and pathology by the circadian clock. J Exp Med 2018;215:1059-68.
139. Woldt E, Sebti Y, Solt LA, et al. Rev-erb-α modulates skeletal muscle oxidative capacity by regulating mitochondrial biogenesis and autophagy. Nat Med 2013;19:1039-46.
140. Huang G, Zhang F, Ye Q, Wang H. The circadian clock regulates autophagy directly through the nuclear hormone receptor Nr1d1/Rev-erbα and indirectly via Cebpb/(C/ebpβ) in zebrafish. Autophagy 2016;12:1292-309.
141. Arnulf I, Nielsen J, Lohmann E, et al. Rapid eye movement sleep disturbances in Huntington disease. Arch Neurol 2008;65:482-8.
142. Diago EB, Martínez-Horta S, Lasaosa SS, et al. Circadian rhythm, cognition, and mood disorders in Huntington’s disease. J Huntingtons Dis 2018;7:193-8.
143. Epping EA, Paulsen JS. Depression in the early stages of Huntington disease. Neurodegener Dis Manag 2011;1:407-14.
144. Saenz-Farret M, Zúñiga-Ramirez C, Ramirez-Gomez CC, Montilla-Uzcategui V, Micheli F. Neuropsychiatric symptoms and premanifest Huntington’s disease. Mov Disord 2017;32:481.
145. Orsolic I, Carrier A, Esteller M. Genetic and epigenetic defects of the RNA modification machinery in cancer. Trends Genet 2023;39:74-88.
146. He PC, He C. m6A RNA methylation: from mechanisms to therapeutic potential. EMBO J 2021;40:e105977.
147. Chen XY, Zhang J, Zhu JS. The role of m6A RNA methylation in human cancer. Mol Cancer 2019;18:103.
148. Qu J, Yan H, Hou Y, et al. RNA demethylase ALKBH5 in cancer: from mechanisms to therapeutic potential. J Hematol Oncol 2022;15:8.
149. Jiang X, Liu B, Nie Z, et al. The role of m6A modification in the biological functions and diseases. Signal Transduct Target Ther 2021;6:74.
150. Wang X, Zhao BS, Roundtree IA, et al. N6-methyladenosine modulates messenger RNA translation efficiency. Cell 2015;161:1388-99.
151. Shi H, Wang X, Lu Z, et al. YTHDF3 facilitates translation and decay of N6-methyladenosine-modified RNA. Cell Res 2017;27:315-28.
152. Huang H, Weng H, Sun W, et al. Recognition of RNA N6-methyladenosine by IGF2BP proteins enhances mRNA stability and translation. Nat Cell Biol 2018;20:285-95.
153. Li J, Zhang H, Wang H. N1-methyladenosine modification in cancer biology: current status and future perspectives. Comput Struct Biotechnol J 2022;20:6578-85.
154. Chatterjee B, Shen CJ, Majumder P. RNA modifications and RNA metabolism in neurological disease pathogenesis. Int J Mol Sci 2021;22:11870.
155. Song H, Zhang J, Liu B, et al. Biological roles of RNA m5C modification and its implications in Cancer immunotherapy. Biomark Res 2022;10:15.
156. Nishikura K. A-to-I editing of coding and non-coding RNAs by ADARs. Nat Rev Mol Cell Biol 2016;17:83-96.
157. Weng YL, Wang X, An R, et al. Epitranscriptomic m6A regulation of axon regeneration in the adult mammalian nervous system. Neuron 2018;97:313-25.e6.
158. Kan L, Ott S, Joseph B, et al. Publisher correction: a neural m6A/Ythdf pathway is required for learning and memory in Drosophila. Nat Commun 2021;12:1743.
159. Zhang Z, Wang M, Xie D, et al. METTL3-mediated N6-methyladenosine mRNA modification enhances long-term memory consolidation. Cell Res 2018;28:1050-61.
160. Li M, Zhao X, Wang W, et al. Ythdf2-mediated m6A mRNA clearance modulates neural development in mice. Genome Biol 2018;19:69.
161. Lence T, Akhtar J, Bayer M, et al. m6A modulates neuronal functions and sex determination in Drosophila. Nature 2016;540:242-7.
162. Chen D, Cheung H, Lau HCH, Yu J, Wong CC. N6-methyladenosine RNA-binding protein YTHDF1 in gastrointestinal cancers: function, molecular mechanism and clinical implication. Cancers 2022;14:3489.
164. Luo L, Zhen Y, Peng D, et al. The role of N6-methyladenosine-modified non-coding RNAs in the pathological process of human cancer. Cell Death Discov 2022;8:325.
165. Yu J, Chen M, Huang H, et al. Dynamic m6A modification regulates local translation of mRNA in axons. Nucleic Acids Res 2018;46:1412-23.
166. Yen YP, Chen JA. The m6A epitranscriptome on neural development and degeneration. J Biomed Sci 2021;28:40.
167. Han B, Yao HH. N6-methyladenosine as a novel regulator of brain physiology and diseases. Curr Med Sci 2020;40:401-6.
168. Nassan M, Videnovic A. Circadian rhythms in neurodegenerative disorders. Nat Rev Neurol 2022;18:7-24.
169. Fischer R, Maier O. Interrelation of oxidative stress and inflammation in neurodegenerative disease: role of TNF. Oxid Med Cell Longev 2015;2015:610813.
170. Han M, Liu Z, Xu Y, et al. Abnormality of m6A mRNA methylation is involved in Alzheimer’s disease. Front Neurosci 2020;14:98.
171. Geng Y, Long X, Zhang Y, et al. FTO-targeted siRNA delivery by MSC-derived exosomes synergistically alleviates dopaminergic neuronal death in Parkinson’s disease via m6A-dependent regulation of ATM mRNA. J Transl Med 2023;21:652.
172. He H, Zhang Q, Liao J, et al. METTL14 is decreased and regulates m6A modification of α-synuclein in Parkinson’s disease. J Neurochem 2023;166:609-22.
173. McMillan M, Gomez N, Hsieh C, et al. RNA methylation influences TDP43 binding and disease pathogenesis in models of amyotrophic lateral sclerosis and frontotemporal dementia. Mol Cell 2023;83:219-36.e7.
174. Pupak A, Singh A, Sancho-Balsells A, et al. Altered m6A RNA methylation contributes to hippocampal memory deficits in Huntington’s disease mice. Cell Mol Life Sci 2022;79:416.
175. Nguyen TB, Miramontes R, Chillon-Marinas C, et al. Aberrant splicing in Huntington’s disease via disrupted TDP-43 activity accompanied by altered m6A RNA modification. bioRxiv. [Preprint.] Nov 2, 2023 [accessed 2024 Sep 20]. Available from: https://www.biorxiv.org/content/10.1101/2023.10.31.565004v1.
176. Zheng Q, Gan H, Yang F, et al. Cytoplasmic m1A reader YTHDF3 inhibits trophoblast invasion by downregulation of m1A-methylated IGF1R. Cell Discov 2020;6:12.
177. Qi Z, Zhang C, Jian H, et al. N1-Methyladenosine modification of mRNA regulates neuronal gene expression and oxygen glucose deprivation/reoxygenation induction. Cell Death Discov 2023;9:159.
178. Bohnsack MT, Sloan KE. The mitochondrial epitranscriptome: the roles of RNA modifications in mitochondrial translation and human disease. Cell Mol Life Sci 2018;75:241-60.
179. Bohnsack KE, Höbartner C, Bohnsack MT. Eukaryotic 5-methylcytosine (m5C) RNA methyltransferases: mechanisms, cellular functions, and links to disease. Genes 2019;10:102.
180. Reid R, Greene PJ, Santi DV. Exposition of a family of RNA m5C methyltransferases from searching genomic and proteomic sequences. Nucleic Acids Res 1999;27:3138-45.
181. PerezGrovas-Saltijeral A, Rajkumar AP, Knight HM. Differential expression of m5C RNA methyltransferase genes NSUN6 and NSUN7 in Alzheimer’s disease and traumatic brain injury. Mol Neurobiol 2023;60:2223-35.
182. Knight HM, Demirbugen Öz M, PerezGrovas-Saltijeral A. Dysregulation of RNA modification systems in clinical populations with neurocognitive disorders. Neural Regen Res 2024;19:1256-61.
183. Borchardt EK, Martinez NM, Gilbert WV. Regulation and function of RNA pseudouridylation in human cells. Annu Rev Genet 2020;54:309-36.
184. Angelova MT, Dimitrova DG, Dinges N, et al. The emerging field of epitranscriptomics in neurodevelopmental and neuronal disorders. Front Bioeng Biotechnol 2018;6:46.
185. Nainar S, Marshall PR, Tyler CR, Spitale RC, Bredy TW. Evolving insights into RNA modifications and their functional diversity in the brain. Nat Neurosci 2016;19:1292-8.
186. Diez-Roux G, Banfi S, Sultan M, et al. A high-resolution anatomical atlas of the transcriptome in the mouse embryo. PLoS Biol 2011;9:e1000582.
187. Shaheen R, Han L, Faqeih E, et al. A homozygous truncating mutation in PUS3 expands the role of tRNA modification in normal cognition. Hum Genet 2016;135:707-13.
188. de Brouwer APM, Abou Jamra R, Körtel N, et al. Variants in PUS7 cause intellectual disability with speech delay, microcephaly, short stature, and aggressive behavior. Am J Hum Genet 2018;103:1045-52.
189. Shaheen R, Tasak M, Maddirevula S, et al. PUS7 mutations impair pseudouridylation in humans and cause intellectual disability and microcephaly. Hum Genet 2019;138:231-9.
190. Torres M, Becquet D, Franc JL, François-Bellan AM. Circadian processes in the RNA life cycle. Wiley Interdiscip Rev RNA 2018;9:e1467.
191. Cao R, Gkogkas CG, de Zavalia N, et al. Light-regulated translational control of circadian behavior by eIF4E phosphorylation. Nat Neurosci 2015;18:855-62.
192. McGlincy NJ, Valomon A, Chesham JE, Maywood ES, Hastings MH, Ule J. Regulation of alternative splicing by the circadian clock and food related cues. Genome Biol 2012;13:R54.
193. Derti A, Garrett-Engele P, Macisaac KD, et al. A quantitative atlas of polyadenylation in five mammals. Genome Res 2012;22:1173-83.
194. Hernández G, Vazquez-Pianzola P. eIF4E as a molecular wildcard in metazoans RNA metabolism. Biol Rev Camb Philos Soc 2023;98:2284-306.
195. Lipton JO, Yuan ED, Boyle LM, et al. The circadian protein BMAL1 regulates translation in response to S6K1-mediated phosphorylation. Cell 2015;161:1138-51.
196. Parnell AA, De Nobrega AK, Lyons LC. Translating around the clock: multi-level regulation of post-transcriptional processes by the circadian clock. Cell Signal 2021;80:109904.
197. Barajas JM, Lin CH, Sun HL, et al. METTL3 regulates liver homeostasis, hepatocyte ploidy, and circadian rhythm-controlled gene expression in mice. Am J Pathol 2022;192:56-71.
198. Wang CY, Yeh JK, Shie SS, Hsieh IC, Wen MS. Circadian rhythm of RNA N6-methyladenosine and the role of cryptochrome. Biochem Biophys Res Commun 2015;465:88-94.
199. Zhong X, Yu J, Frazier K, et al. Circadian clock regulation of hepatic lipid metabolism by modulation of m6A mRNA methylation. Cell Rep 2018;25:1816-28.e4.
200. Terajima H, Yoshitane H, Ozaki H, et al. ADARB1 catalyzes circadian A-to-I editing and regulates RNA rhythm. Nat Genet 2017;49:146-51.
201. Terajima H, Yoshitane H, Yoshikawa T, Shigeyoshi Y, Fukada Y. A-to-I RNA editing enzyme ADAR2 regulates light-induced circadian phase-shift. Sci Rep 2018;8:14848.
202. Omata Y, Yamauchi T, Tsuruta A, Matsunaga N, Koyanagi S, Ohdo S. RNA editing enzyme ADAR1 governs the circadian expression of P-glycoprotein in human renal cells by regulating alternative splicing of the ABCB1 gene. J Biol Chem 2021;296:100601.
203. Tassinari V, La Rosa P, Guida E, et al. Contribution of A-to-I RNA editing, M6A RNA Methylation, and Alternative Splicing to physiological brain aging and neurodegenerative diseases. Mech Ageing Dev 2023;212:111807.
204. Zhao F, Xu Y, Gao S, et al. METTL3-dependent RNA m6A dysregulation contributes to neurodegeneration in Alzheimer’s disease through aberrant cell cycle events. Mol Neurodegener 2021;16:70.
205. Hess ME, Hess S, Meyer KD, et al. The fat mass and obesity associated gene (Fto) regulates activity of the dopaminergic midbrain circuitry. Nat Neurosci 2013;16:1042-8.
206. Yamashita T, Kwak S. The molecular link between inefficient GluA2 Q/R site-RNA editing and TDP-43 pathology in motor neurons of sporadic amyotrophic lateral sclerosis patients. Brain Res 2014;1584:28-38.
207. Hideyama T, Yamashita T, Suzuki T, et al. Induced loss of ADAR2 engenders slow death of motor neurons from Q/R site-unedited GluR2. J Neurosci 2010;30:11917-25.
208. Raj T, Li YI, Wong G, et al. Integrative transcriptome analyses of the aging brain implicate altered splicing in Alzheimer’s disease susceptibility. Nat Genet 2018;50:1584-92.
209. Liu W, Ma R, Sun C, et al. Implications from proteomic studies investigating circadian rhythm disorder-regulated neurodegenerative disease pathology. Sleep Med Rev 2023;70:101789.
210. Bungeroth M, Appenzeller S, Regulin A, et al. Differential aggregation properties of alpha-synuclein isoforms. Neurobiol Aging 2014;35:1913-9.
211. Tan MMX, Malek N, Lawton MA, et al. Genetic analysis of Mendelian mutations in a large UK population-based Parkinson’s disease study. Brain 2019;142:2828-44.
212. Dietrich P, Dragatsis I. Familial dysautonomia: mechanisms and models. Genet Mol Biol 2016;39:497-514.
213. Hammond SM, Aartsma-Rus A, Alves S, et al. Delivery of oligonucleotide-based therapeutics: challenges and opportunities. EMBO Mol Med 2021;13:e13243.
215. Matsuo M. Antisense oligonucleotide-mediated exon-skipping therapies: precision medicine spreading from duchenne muscular dystrophy. JMA J 2021;4:232-40.
216. Lu QL, Cirak S, Partridge T. What can we learn from clinical trials of exon skipping for DMD? Mol Ther Nucleic Acids 2014;3:e152.
217. Kuijper EC, Bergsma AJ, Pijnappel WWMP, Aartsma-Rus A. Opportunities and challenges for antisense oligonucleotide therapies. J Inherit Metab Dis 2021;44:72-87.
218. Pan Q, Shai O, Lee LJ, Frey BJ, Blencowe BJ. Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat Genet 2008;40:1413-5.
219. Wahl MC, Will CL, Lührmann R. The spliceosome: design principles of a dynamic RNP machine. Cell 2009;136:701-18.
220. Kordyś M, Sen R, Warkocki Z. Applications of the versatile CRISPR-Cas13 RNA targeting system. Wiley Interdiscip Rev RNA 2022;13:e1694.
221. Cox DBT, Gootenberg JS, Abudayyeh OO, et al. RNA editing with CRISPR-Cas13. Science 2017;358:1019-27.
222. Abudayyeh OO, Gootenberg JS, Franklin B, et al. A cytosine deaminase for programmable single-base RNA editing. Science 2019;365:382-6.
223. Rauch S, He C, Dickinson BC. Targeted m6A reader proteins to study epitranscriptomic regulation of single RNAs. J Am Chem Soc 2018;140:11974-81.
224. Wilson C, Chen PJ, Miao Z, Liu DR. Programmable m6A modification of cellular RNAs with a Cas13-directed methyltransferase. Nat Biotechnol 2020;38:1431-40.
225. Li J, Chen Z, Chen F, et al. Targeted mRNA demethylation using an engineered dCas13b-ALKBH5 fusion protein. Nucleic Acids Res 2020;48:5684-94.
226. Akinc A, Maier MA, Manoharan M, et al. The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs. Nat Nanotechnol 2019;14:1084-7.
227. FDA News Release. FDA grants accelerated approval to first drug for Duchenne muscular dystrophy. Available from: https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-first-drug-duchenne-muscular-dystrophy. [Last accessed on 20 Sep 2024].
228. FDA News Release. FDA grants accelerated approval to first targeted treatment for rare Duchenne muscular dystrophy mutation. Available from: https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-first-targeted-treatment-rare-duchenne-muscular-dystrophy-mutation. [Last accessed on 20 Sep 2024].
229. FDA News Release. FDA approves targeted treatment for rare duchenne muscular dystrophy mutation. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-targeted-treatment-rare-duchenne-muscular-dystrophy-mutation. [Last accessed on 20 Sep 2024].
230. Our Pipeline. Building an industry-leading genetic medicine pipeline. Available from: https://www.sarepta.com/products-pipeline/pipeline. [Last accessed on 20 Sep 2024].
231. Ottesen EW. ISS-N1 makes the first FDA-approved drug for spinal muscular atrophy. Transl Neurosci 2017;8:1-6.
232. Gales L. Tegsedi (inotersen): an antisense oligonucleotide approved for the treatment of adult patients with hereditary transthyretin amyloidosis. Pharmaceuticals 2019;12:78.
233. ClinicalTrials.gov. A study of BIIB067 (tofersen) initiated in clinically presymptomatic adults with a confirmed superoxide dismutase 1 mutation (ATLAS). Available from: https://clinicaltrials.gov/study/NCT04856982. [Last accessed on 20 Sep 2024].
234. Crooke ST, Baker BF, Kwoh TJ, et al. Integrated safety assessment of 2’-O-methoxyethyl chimeric antisense oligonucleotides in nonhuman primates and healthy human volunteers. Mol Ther 2016;24:1771-82.
235. Agrawal S, Joshi M, Christoforidis JB. Vitreous inflammation associated with intravitreal anti-VEGF pharmacotherapy. Mediators Inflamm 2013;2013:943409.
236. Boyer DS, Goldbaum M, Leys AM, Starita C. V. I.S.I.O.N. Study Group. Effect of pegaptanib sodium 0.3 mg intravitreal injections (Macugen) in intraocular pressure: posthoc analysis from V.I.S.I.O.N. study. Br J Ophthalmol 2014;98:1543-6.
237. Falavarjani KG, Nguyen QD. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye 2013;27:787-94.
238. Anthony K, Gallo JM. Aberrant RNA processing events in neurological disorders. Brain Res 2010;1338:67-77.
239. Chang JL, Hinrich AJ, Roman B, et al. Targeting amyloid-β precursor protein, APP, splicing with antisense oligonucleotides reduces toxic amyloid-β production. Mol Ther 2018;26:1539-51.
240. Daoutsali E, Hailu TT, Buijsen RAM, et al. Antisense oligonucleotide-induced amyloid precursor protein splicing modulation as a therapeutic approach for dutch-type cerebral amyloid angiopathy. Nucleic Acid Ther 2021;31:351-63.
241. Rueter SM, Dawson TR, Emeson RB. Regulation of alternative splicing by RNA editing. Nature 1999;399:75-80.
242. Kluesner MG, Lahr WS, Lonetree CL, et al. CRISPR-Cas9 cytidine and adenosine base editing of splice-sites mediates highly-efficient disruption of proteins in primary and immortalized cells. Nat Commun 2021;12:2437.
243. Long C, Li H, Tiburcy M, et al. Correction of diverse muscular dystrophy mutations in human engineered heart muscle by single-site genome editing. Sci Adv 2018;4:eaap9004.
